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Insulin pump therapy and continuous  
systems use in adult type 1 diabetes patients 
— Experts’ Opinion 
In the 21st century, technological progress changed 
the therapy of patients with type 1 diabetes. Modern 
personal insulin pumps, and most of all continuous 
glucose monitoring (CGM) systems, improve the safety 
and comfort of life of patients with diabetes who re-
quire insulin administration. Insulin therapy with the 
use of CGM enables achieving a glycemic goal close to 
normoglycemia without an increased risk of hypogly-
cemia and, above all, prevents chronic complications 
of diabetes. This is especially important for people who 
are unaware of hypoglycaemia.
The reimbursement of the continuous glucose 
monitoring system in children and young adults < 26 
years of age treated with continuous subcutaneous 
insulin infusion (CSII) with the use of a personal insulin 
pump has increased the availability of new technolo-
gies improving the safety and effectiveness of insulin 
therapy for patients with type 1 diabetes in Poland. The 
community of diabetes health care professionals is 
concerned about the fact that there is no reimburse-
ment for adults older than 26 years of age, and par-
ticularly worrying are situations when, due to the 
discontinuation of reimbursement, a patient with 
impaired hypoglycemia awareness is deprived of 
a therapy that provides safety in terms of health and 
life and improves the quality of life. With the benefit 
of the patient and broadly understood social welfare 
in mind, we have developed the Healthcare Provision 
Charter “Real-Time Continuous Glucose Monitoring 
System (RT-CGM) in adults over 26 years of age with 
type 1 diabetes and hypoglycemia unawareness (i.e. 
the lack of prodromal symptoms of hypoglycemia) who 
are treated with an insulin pump”. This document is 
the basis for starting a process aimed at reimbursing 
continuous glucose monitoring in patients over 26 years 
of age. We trust that this action, which is in line with 
the recent decisions of the Ministry of Health that are 
beneficial for diabetic patients, will become another 
good investment in health of Poles. 
There is a consensus of opinions that the extension 
of CGM reimbursement will contribute to the improve-
ment of the quality of care for patients with diabetes 
in Poland. A key element of qualitative changes would 
be guaranteed patient education services aimed at 
providing the patient with knowledge and skills to inde-
pendently operate the CGM system, correctly calibrate 
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it, interpret the direction and rate of changes in blood 
glucose (glycemic trends), respond to changing blood 
glucose values and program alarms. 
Weighing the needs and opportunities, we in-
cluded in the Healthcare Provision Charter adults with 
type 1 diabetes and impaired hypoglycemia awareness 
who have used insulin pump for 12 months in the last 
18 months. This Expert Consensus Statement expresses 
special concern for adult patients with type 1 diabetes 
who are living with this disease for several dozen years 
and whose treatment with new technologies is often 
conditioned by a good economic status and ability to 
incur costs related to the use of CGM.
Clinical benefits of providing access to the CGM 
system and education in the use of the CGM system in 
adults with type 1 diabetes include the reduction of hy-
poglycemia and hyperglycemia episodes (which means 
more time spent in the glycemic target range), better 
quality of life and, above all, reduced risk of develop-
ment and progression of acute and chronic diabetes 
complications. It is particularly important to reduce 
the frequency of severe hypoglycemia, which is a life 
threatening condition. Decreased rate of hypoglycemia 
will also contribute to the reduction of costs related 
to hospitalization, absenteeism and presenteeism in 
the workplace.
This technology not only improves the quality of 
diabetes care and increases the safety of insulin therapy, 
but also allows communication, analysis and conclu-
sions, making e-counseling very effective. It turned out 
that the use of CGM and innovative telemedicine tech-
nology is possible and especially helpful for patients 
during the COVID-19 pandemic.
The position statement on the monitoring and 
treatment of type 1 diabetes in adult patients with 
the use of insulin pumps and a continuous glycemic 
monitoring system is in line with the social need and 
the creation of modern healthcare involving telemedi-
cine. In the face of the global COVID-19 pandemic, 
the value of technologies allowing for monitoring 
and assessing patients from a distance is even more 
apparent.
Our opinion is consistent with the 2020 Guidelines 
on the management of diabetic patients. A position of 
Diabetes Poland which indicates therapeutic goals for 
diabetes treatment based on the use of continuous 
glucose monitoring systems. These guidelines also em-
phasize the importance of telemedicine in optimizing 
diabetes control.
The community of diabetes health care professionals 
appreciates the steps taken by the Ministry of Health to 
improve the quality of treatment for diabetics in Poland. 
Diabetes was on the list of national health priorities 
defined by the regulation of the Minister of Health of 
February 27, 2018, next to cardiovascular diseases, cancer 
and respiratory diseases [1]. This priority should be real-
ized through education and increasing access of patients 
to diagnostic tools and methods of monitoring the pro-
gress and effects of diabetes therapy. In 2018–2020, the 
decisions of the Ministry of Health led to a significant 
improvement in the access of patients with diabetes to 
publicly reimbursed medical technologies and drugs.
Telephone consultations, remote blood glucose 
monitoring (e.g. using RT-CGM) and video consulta-
tions are the most frequently studied telemedicine 
interventions, each of them leading to increased ac-
cess to specialist diabetes care. Unlike in cardiology, in 
diabetology, telemedicine solutions are rarely used in 
the healthcare system, despite the fact that, according 
to clinical trials, they translate into improved glycemic 
control and even reduced the risk of hypoglycaemia [2].
Increasing the availability of continuous glucose 
monitoring systems and relevant education in the use 
of CGM for patients with diabetes aged > 26 years 
who are treated with a personal insulin pump would 
constitute another positive breakthrough in diabetes 
care in our country.
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